The reduction of concomitant glucocorticoids dosage following treatment with IL-1 receptor antagonist in adult onset Still's disease. A systematic review and meta-analysis of observational studies.
Roberto CaporaliFrancesco UrsiniJurgen SotaRoberto De GiorgioLuca CantariniRoberto GiacomelliPublished in: Therapeutic advances in musculoskeletal disease (2020)
In conclusion, the present systematic review and meta-analysis suggests the reduction of concomitant GCs dosage following treatment with anakinra. A percentage of patients are no longer required to be treated with GCs, discontinuing these drugs without a flare of the disease.